论文部分内容阅读
同步放化疗(CRCT)是近年发展起来的肿瘤综合治疗的一种新模式,不可手术的局部晚期非小细胞肺癌(NSCLC)患者约占45%,CRCT是不可切除的局部晚期NSCLC的标准治疗,以铂类为基础的化疗与同步胸腔放疗使局部晚期NSCLC患者5年生存率接近15%,但局部复发及远处转移仍是治疗失败的主要原因。为进一步提高局部晚期NSCLC疗效,国内外对CRCT进行了广泛的研究,并取得一定疗效,但对CRCT的最佳治疗模式仍存有许多争议,同时靶向治疗与CRCT的联合成了新的热点。现就近年来局部晚期NSCLC CRCT临床研究进展作一综述。
Synchrocherapy (CRCT) is a new model of integrated cancer therapy developed in recent years. About 45% of patients with locally advanced unresectable non-small cell lung cancer (NSCLC), CRCT is the standard treatment for unresectable locally advanced NSCLC, Platinum-based chemotherapy and concurrent chest radiotherapy make the 5-year survival rate of patients with locally advanced NSCLC close to 15%, but local recurrence and distant metastasis are still the main reasons for the failure of treatment. To further improve the efficacy of locally advanced NSCLC, CRCT has been studied extensively at home and abroad and achieved some curative effects. However, there are still many controversies about the optimal treatment of CRCT. At the same time, the combination of targeted therapy and CRCT has become a new hot spot . The progress of clinical research on locally advanced NSCLC in recent years is reviewed.